The Correlation between Interleukin-18, Vascular Endothelial Growth Factor Expression and Clinicopathologic Parameters for Invasive Breast Cancer_West China Medical Journal

Authors：

LIU Xuejuan , ZHANG Qian ,  WANG Jing

Department of Thyroid and Breast Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

WANG Jing, Email: juanlx@126.com

Keywords：

乳腺癌; 白细胞介素18; 血管内皮生长因子; 表达

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　通过检测浸润性乳腺癌中白细胞介素18（IL-18）和血管内皮生长因子（VEGF）的表达情况，探讨其表达相关性及与临床病理学参数的关系。方法　应用免疫组织化学法检测IL-18和VEGF在42例浸润性乳腺癌组织和12例正常乳腺组织中的表达情况。结果　IL-18和VEGF在42例浸润性乳腺癌中的表达阳性率均显著高于12例正常乳腺组织（P＜0.05）。且在42例浸润性乳腺癌组织中，IL-18阳性组中VEGF阳性率（87.1%）显著高于IL-18阴性组中VEGF阳性率（12.9%），差异有统计学意义（P＜0.05）。在亚组分析中，IL-18的表达只与有无腋窝淋巴结转移有相关性（P＜0.05），而VEGF的表达与有无腋窝淋巴结转移和TNM分期有相关性（P＜0.05）。结论　在浸润性乳腺癌中，IL-18的表达上调与VEGF的表达上调显著相关，IL-18可能具有促进肿瘤新生血管形成的作用。

Citation： LIU Xuejuan,ZHANG Qian,WANG Jing. The Correlation between Interleukin-18, Vascular Endothelial Growth Factor Expression and Clinicopathologic Parameters for Invasive Breast Cancer. West China Medical Journal, 2012, 27(10): 1458-1461. doi: Copy

1.	Kim KE, Song H, Kim TS, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines[J]. Oncogene, 2007, 26(10): 1468-1476.
2.	Kang JS, Bae SY, Kim HR, et al. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44[J]. Carcinogenesis, 2009, 30(12): 1987-1996.
3.	Nong SJ, Zhang YP, Zhou SJ, et al. Relationship between serum IL-18 and VEGF levels in patients with prostate cancer[J]. Chinese-German J Clin Oncol, 2010, 9(11): 643-647.
4.	Tsuboi K, Tatsuya M, Nakajima M, et al. Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma[J]. Cancer Lett, 2004, 205(2): 207-214.
5.	Jebreel A, Mistry D, Loke D, et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer[J]. J Laryngol Otol, 2007, 121(3): 246-252.
6.	Park H, Byun D, Kim TS, et al. Enhanced IL-18 expression in common skin tumors[J]. Immunol Lett, 2001, 79(3): 215-219.
7.	Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression[J]. Cancer Metastasis Rev, 2006, 25(3): 417-434.
8.	Xia D, Zheng S, Zhang W, et al. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen[J]. J Mol Med, 2003, 81(9): 585-596.
9.	Okamura H, Tsutsui H, Kashiwamura S, et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity[J]. Adv Immunol, 1998, 70: 281-312.
10.	Marshall DJ, Rudnick KA, Mccarthy SG, et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine[J]. Vaccine, 2006, 24(3): 244-253.
11.	Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF[J]. Science, 1999, 284(5422): 1994-1998.
12.	Asahara T, Kalka C, Isner JM, et al. Stem cell therapy and gene transfer for regeneration[J]. Gene Ther, 2000, 7(6): 451-457.
13.	Rafii S. Circulating endothelial precursors: mystery, reality, and promise[J]. J Clin Invest, 2000, 105(1): 17-19.
14.	Conti CJ. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy[J]. Oncologist, 2002, 7 Suppl 3(3): 4-11.
15.	Bandoh N, Hayashi T, Takahara M, et al. VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis[J]. Cancer Lett, 2004, 208(2): 215-225.
16.	Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways[J]. Immunol Lett, 2006, 103(2): 159-166.
17.	Amin MA, Rabquer BJ, Mansfield PJ, et al. Interleukin 18 induces angiogenesis in vitro and in vitro via Src and Jnk kinases[J]. Ann Rheum Dis, 2010, 69(12): 2204-2212.
18.	Grimm D, Bauer J, Ulbrich C, et al. Different responsiveness of endothelial cells to vascular endothelial growth factor and basic fibroblast growth factor added to culture media under gravity and simulated microgravity[J]. Tissue Eng Part A, 2010, 16(5): 1559-1573.
19.	Qiao H, Sonoda KH, Sassa Y, et al. Abnormal retinal vascular development in IL-18 knockout mice[J]. Lab Invest, 2004, 84(8): 973-980.
20.	Qiao H, Sonoda KH, Ikeda Y, et al. Interleukin-18 regulates pathological intraocular neovascularization[J]. J Leukoc Biol, 2007, 81(4): 1012-1021.
21.	Günel N, Co?kun U, Sancak B, et al. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients[J]. Cancer, 2002, 95(3): 663-667.
22.	Crohns M, Saarelainen S, Laine S, et al. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy-association of interleukin-8 and VEGF with survival[J]. Cytokine, 2010, 50(1): 30-36.
23.	Coskun U, Gunel N, Sancak B, et al. Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients[J]. Clin Exp Immunol, 2004, 137(3): 546-551.
24.	Merendino RA, Gangemi S, Ruello A, et al. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations[J]. Int J Biol Markers, 2001, 16(2): 126-129.
25.	Carbone A, Vizio B, Novarino A, et al. IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival[J]. J Immunother, 2009, 32(9): 920-931.

1. 　Kim KE, Song H, Kim TS, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines[J]. Oncogene, 2007, 26(10): 1468-1476.
2. 　Kang JS, Bae SY, Kim HR, et al. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44[J]. Carcinogenesis, 2009, 30(12): 1987-1996.
3. 　Nong SJ, Zhang YP, Zhou SJ, et al. Relationship between serum IL-18 and VEGF levels in patients with prostate cancer[J]. Chinese-German J Clin Oncol, 2010, 9(11): 643-647.
4. 　Tsuboi K, Tatsuya M, Nakajima M, et al. Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma[J]. Cancer Lett, 2004, 205(2): 207-214.
5. 　Jebreel A, Mistry D, Loke D, et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer[J]. J Laryngol Otol, 2007, 121(3): 246-252.
6. 　Park H, Byun D, Kim TS, et al. Enhanced IL-18 expression in common skin tumors[J]. Immunol Lett, 2001, 79(3): 215-219.
7. 　Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression[J]. Cancer Metastasis Rev, 2006, 25(3): 417-434.
8. 　Xia D, Zheng S, Zhang W, et al. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen[J]. J Mol Med, 2003, 81(9): 585-596.
9. 　Okamura H, Tsutsui H, Kashiwamura S, et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity[J]. Adv Immunol, 1998, 70: 281-312.
10. 　Marshall DJ, Rudnick KA, Mccarthy SG, et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine[J]. Vaccine, 2006, 24(3): 244-253.
11. 　Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF[J]. Science, 1999, 284(5422): 1994-1998.
12. 　Asahara T, Kalka C, Isner JM, et al. Stem cell therapy and gene transfer for regeneration[J]. Gene Ther, 2000, 7(6): 451-457.
13. 　Rafii S. Circulating endothelial precursors: mystery, reality, and promise[J]. J Clin Invest, 2000, 105(1): 17-19.
14. 　Conti CJ. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy[J]. Oncologist, 2002, 7 Suppl 3(3): 4-11.
15. 　Bandoh N, Hayashi T, Takahara M, et al. VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis[J]. Cancer Lett, 2004, 208(2): 215-225.
16. 　Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways[J]. Immunol Lett, 2006, 103(2): 159-166.
17. 　Amin MA, Rabquer BJ, Mansfield PJ, et al. Interleukin 18 induces angiogenesis in vitro and in vitro via Src and Jnk kinases[J]. Ann Rheum Dis, 2010, 69(12): 2204-2212.
18. 　Grimm D, Bauer J, Ulbrich C, et al. Different responsiveness of endothelial cells to vascular endothelial growth factor and basic fibroblast growth factor added to culture media under gravity and simulated microgravity[J]. Tissue Eng Part A, 2010, 16(5): 1559-1573.
19. 　Qiao H, Sonoda KH, Sassa Y, et al. Abnormal retinal vascular development in IL-18 knockout mice[J]. Lab Invest, 2004, 84(8): 973-980.
20. 　Qiao H, Sonoda KH, Ikeda Y, et al. Interleukin-18 regulates pathological intraocular neovascularization[J]. J Leukoc Biol, 2007, 81(4): 1012-1021.
21. 　Günel N, Co?kun U, Sancak B, et al. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients[J]. Cancer, 2002, 95(3): 663-667.
22. 　Crohns M, Saarelainen S, Laine S, et al. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy-association of interleukin-8 and VEGF with survival[J]. Cytokine, 2010, 50(1): 30-36.
23. 　Coskun U, Gunel N, Sancak B, et al. Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients[J]. Clin Exp Immunol, 2004, 137(3): 546-551.
24. 　Merendino RA, Gangemi S, Ruello A, et al. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations[J]. Int J Biol Markers, 2001, 16(2): 126-129.
25. 　Carbone A, Vizio B, Novarino A, et al. IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival[J]. J Immunother, 2009, 32(9): 920-931.

West China Medical Journal

The Correlation between Interleukin-18, Vascular Endothelial Growth Factor Expression and Clinicopathologic Parameters for Invasive Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content